OBJECTIVE: The purpose of this study was to investigate the association between the metabotropic glutamate receptor subtype 7 (mGluR7) gene (GRM7) polymorphism and treatment response to methylphenidate in Korean children with attention-deficit/hyperactivity disorder (ADHD). METHODS: We enrolled 175 medication-naïve children with ADHD in an open-label 8 week trial of methylphenidate. The participants were genotyped and evaluated using the Clinical Global Impressions (CGI) Scale and the parent version of the ADHD Rating Scale-IV (ADHD-RS) before and after treatment. RESULTS: After the 8 week course of methylphenidate, children with the GRM7 rs37952452 polymorphism G/A genotype had a more pronounced response rate to the treatment than did children with the G/G genotype according to the ADHD-RS scores (72.2% vs. 55.4%, respectively; p=0.011) and the more stringent standard of combined ADHD-RS and CGI-Improvement (CGI-I) scores (50.0% vs. 35.3%, respectively; p=0.044). CONCLUSIONS: The present study suggests that the GRM7 rs37952452 polymorphism may play a role in the treatment response to methylphenidate in children with ADHD. Further studies to evaluate the association between glutamate genes and treatment response to methylphenidate in children with ADHD, including a replication of our findings using a control or comparative group in a larger sample, are warranted.
OBJECTIVE: The purpose of this study was to investigate the association between the metabotropic glutamate receptor subtype 7 (mGluR7) gene (GRM7) polymorphism and treatment response to methylphenidate in Korean children with attention-deficit/hyperactivity disorder (ADHD). METHODS: We enrolled 175 medication-naïve children with ADHD in an open-label 8 week trial of methylphenidate. The participants were genotyped and evaluated using the Clinical Global Impressions (CGI) Scale and the parent version of the ADHD Rating Scale-IV (ADHD-RS) before and after treatment. RESULTS: After the 8 week course of methylphenidate, children with the GRM7rs37952452 polymorphism G/A genotype had a more pronounced response rate to the treatment than did children with the G/G genotype according to the ADHD-RS scores (72.2% vs. 55.4%, respectively; p=0.011) and the more stringent standard of combined ADHD-RS and CGI-Improvement (CGI-I) scores (50.0% vs. 35.3%, respectively; p=0.044). CONCLUSIONS: The present study suggests that the GRM7rs37952452 polymorphism may play a role in the treatment response to methylphenidate in children with ADHD. Further studies to evaluate the association between glutamate genes and treatment response to methylphenidate in children with ADHD, including a replication of our findings using a control or comparative group in a larger sample, are warranted.
Authors: Craig W Lindsley; Kyle A Emmitte; Corey R Hopkins; Thomas M Bridges; Karen J Gregory; Colleen M Niswender; P Jeffrey Conn Journal: Chem Rev Date: 2016-02-16 Impact factor: 60.622
Authors: Carson W Reed; Jacob J Kalbfleisch; Madison J Wong; Jordan P Washecheck; Ashton Hunter; Alice L Rodriguez; Anna L Blobaum; P Jeffrey Conn; Colleen M Niswender; Craig W Lindsley Journal: ACS Med Chem Lett Date: 2020-08-20 Impact factor: 4.345
Authors: Nicole M Fisher; Robert W Gould; Rocco G Gogliotti; Annalise J McDonald; Hana Badivuku; Susmita Chennareddy; Aditi B Buch; Annah M Moore; Matthew T Jenkins; W Hudson Robb; Craig W Lindsley; Carrie K Jones; P Jeffrey Conn; Colleen M Niswender Journal: Genes Brain Behav Date: 2020-04-14 Impact factor: 3.449
Authors: Masahito Abe; Mabel Seto; Rocco G Gogliotti; Matthew T Loch; Katrina A Bollinger; Sichen Chang; Eileen M Engelberg; Vincent B Luscombe; Joel M Harp; Michael Bubser; Darren W Engers; Carrie K Jones; Alice L Rodriguez; Anna L Blobaum; P Jeffrey Conn; Colleen M Niswender; Craig W Lindsley Journal: ACS Med Chem Lett Date: 2017-09-01 Impact factor: 4.345